NCT01358825View on ClinicalTrials.gov

Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

May 30, 2011

Primary Completion Date

July 15, 2011

Study Completion Date

July 15, 2011

Conditions
TetanusPoliomyelitisHaemophilus Influenzae Type bAcellular PertussisDiphtheriaHepatitis BDiphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines
Interventions
PROCEDURE

Blood Sampling

A blood sample will be taken at 5 years of age, after vaccination in the primary study.

Trial Locations (4)

5124

GSK Investigational Site, Morvik

0130

GSK Investigational Site, Oslo

SE-702 11

GSK Investigational Site, Örebro

SE-901 85

GSK Investigational Site, Umeå

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01358825 - Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ | Biotech Hunter | Biotech Hunter